IQInvest research note
24 SEP 2026 · 21:23 ET
BMY
Bristol-Myers Squibb Company
$61.50
$0.35 (+0.57%)up 0.57%
24 September 2026 · delayed 15+ min
C-
Cut-offs are the grader's own: 97+ for an A+, below 60 is an F.
Bristol-Myers Squibb Company earns a C- on good profit margins (>10%) and strong ROE (>20%) but high debt-to-equity ratio (>2.0) and MACD bearish (negative histogram). Reasonable investment with moderate upside potential.
Adjusted for Moderate investors, Medium-term investors 6.0% suggested allocation Change these
IQ-BMY-20260924engine v1 · 7-category weighted scorecard